
Opinion|Videos|December 12, 2025
The Effects of Thrombocytopenia at Diagnosis of MDS
Author(s)Caleb J. Scheckel, DO , Clark Alsfeld, MD
A recent study reveals thrombocytopenia as a significant prognostic factor in low-risk MDS, impacting survival and treatment strategies.
Advertisement
Episodes in this series

A recent abstract from the 2025 American Society of Hematology (ASH) meeting examined the prognostic impact of thrombocytopenia at diagnosis in Myelodysplastic Syndromes (MDS). The findings align with growing evidence that low platelet counts at diagnosis, or an early subsequent drop, are associated with worse clinical outcomes. For instance, studies show patients with low platelet counts decline in the first 6 months have significantly inferior overall survival and higher risk of progression to acute myeloid leukemia.
Advertisement
Related to this article

Mark A. Lewis, MD, explains when unexpected disease behavior in neuroendocrine tumors should prompt a specialist referral and how patients can still be treated close to home.

Updated LEGEND trial data show durable responses with detalimogene in BCG-unresponsive NMIBC, supporting a planned BLA submission by year-end 2026.

The FDA issued a complete response letter to the biologics license application for ivonescimab for use in combination with chemotherapy in EGFR-mutated NSCLC.

Crossover to bezuclastinib plus sunitinib after progression on sunitinib improved PFS and responses in GIST in phase 3 PEAK, with no new safety signals.

Arvind Dasari, MD, MS, explains how to sequence radioligand therapy, cabozantinib, and everolimus in well-differentiated neuroendocrine tumors.

A survey of US veterans with non-muscle invasive bladder cancer identifies barriers to treatment access, care coordination challenges, and gaps in patient education.

The perioperative regimen improved event-free and overall survival in the phase 3 VOLGA trial, offering a new option for patients with muscle-invasive bladder cancer who cannot receive or decline cisplatin.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Does Not Approve Ivonescimab for EGFR-Mutant NSCLC
2
Dr Dasari on Sequencing RLT, Cabozantinib, and Everolimus in NETs
3
Crossover to Bezuclastinib Plus Sunitinib Improves Disease Control in Pretreated GIST
4
FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
5

